Nutcracker Therapeutics’ Post

Cell and gene therapies in the EU offer new hope in treating previously untreatable illnesses. The advancement of cell and gene therapies has led to crucial partnerships between contract research organizations and specialty logistics in CGT clinical trials. These partnerships have unveiled strategies and insights for success in this rapidly evolving field. Download our whitepaper for more: https://ow.ly/rweH50RcqQ5

Immune rejection is a major drawback with any cell therapy. One way to overcome this is to interfere with the immune recognition properties of the therapeutic cell by gene editing. For example, the HLA 1 system can be modulated by knocking out the B2M gene, which controls recognition of the therapeutic cell by the immune system. To find out how our StemEdit Clinical Gene Editing can help your project: https://hubs.li/Q02mPY8W0

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/kc4G50Qznic

Thanks to American Society of Gene & Cell Therapy and Citeline for putting together the Q4 #cellandgenetherapy landscape report. The report provides valuable insights into the current state of the cell, gene, and RNA therapy landscape. Check out the full report on asgct.org. #ASGCT #Citeline #biotech #healthcare #innovation

Dr. Ana Moreno, Co-Founder and CEO of Navega Therapeutics, will present our next webinar on Wednesday, November 9. She'll present a novel #epigenetic gene therapy that targets NaV1.7 and has shown to prevent and reverse pain. She'll also how epigenetic gene therapies can be utilized to target previously undruggable targets, such as Nav1.  #TranslationalTuesday #earlyhumaninsights  #drugdiscovery

I will present tomorrow, October 25, at the ESGCT - European Society of Gene & Cell Therapy - 30th Annual Congress in Brussels. I am sharing results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1 #esgct2023 #genetherapy #GaucherDisease

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/kc4G50Qznic

IQVIA’s latest white paper takes an exploratory deep dive into the next decade of cell, gene, and RNA therapies. With insightful contributions from IQVIA experts, join us on a journey of discovery as we step into a new era of pharmacotherapeutics. https://bit.ly/3HNgqXY #CAGT #pharmacotherapeutics

Exciting news! 👏 On January 25th, Cell & Gene Chief Editor, Erin Harris, will welcome the FDA's Dr. Peter Marks and Dr. Nicole Verdun to Cell & Gene LIVE for a discussion on the evolving regulatory landscape in 2024 for cell and gene therapies. Register for this FREE webinar to gain expert insights on cell and gene therapies and stay ahead in the industry! ⬇️ #CellandGeneTherapy #CGT #FDA

Ever wondered about the intricate web of logistics behind #cellandgenetherapy #clinicaltrials? From sourcing specialized equipment to navigating regulatory requirements, every step is crucial in bringing innovative treatments to patients in need. We understand the nuances of these complex supply chains and have developed an end-to-end process to support your cell and gene therapy trial every step of the way.